Prevalence and features of the course of HIV/HCV co-infection in pregnant women
https://doi.org/10.22627/2072-8107-2023-22-2-28-33
Abstract
The aim of the work is to improve the algorithm of management of pregnant women with HIV/HCV co-infection. The study was conducted on the basis of the Moscow City Center for AIDS Prevention and Control of the Moscow Department of Health from 2020 to 2022. 80 women diagnosed with HIV/HCV coinfection were under observation. The patients underwent a general examination and evaluation of anamnesis data, laboratory tests. The article presents statistical data on HIV/HCV-infected women who have been registered at the Moscow City Center for the Prevention and Control of AIDS for the past three years. The social characteristics of pregnant women with HIV/HCV co-infection are given and the clinical and immunological features of the course of the disease are presented.
About the Authors
A. A. Khamatova
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation; Moscow City Center for the Prevention and Control of AIDS, «Infectious Clinical Hospital No. 2» of the Moscow Department of Health
Russian Federation
Russian Federation
Moscow
A. I. Mazus
Moscow City Center for the Prevention and Control of AIDS, «Infectious Clinical Hospital No. 2» of the Moscow Department of Health
Russian Federation
Russian Federation
Moscow
T. A. Chebotareva
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
J. F. Vlatskaya
Moscow City Center for the Prevention and Control of AIDS, «Infectious Clinical Hospital No. 2» of the Moscow Department of Health
Russian Federation
Russian Federation
Moscow
T. A. Tupoleva
National Medical Research Center for Hematology of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Moscow
D. S. Tikhomirov
National Medical Research Center for Hematology of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Moscow
References
1. [UNAIDS. Fact sheet 2022. Global statistics on HIV. (In Russ.)]
2. [WHO. Fact sheet 2022. Hepatitis C. (In Russ.)]
3. [Federal state statistical observation No. 61 "Information on the contingents of patients with HIV infection". (In Russ.)]
4. [Pimenov N.N., Komarova S.V., Karandashova I.V. Hepatitis C and its outcomes in Russia: analysis of incidence, prevalence and mortality before the start of the infection elimination program. Infektsionnyye Bolezni=Infectious Diseases. 2018; 16(3): 37-45. (In Russ.)]
5. EASL recommendations on treatment of hepatitis C: Final update of the series. Journal of hepatology. 2020 Nov; 73(5): 1170—1218. Available at: https://easl.eu/wp-content/uploads/2020/10/ EASL-recommendations-on-treatment-of-hepatitis-C.pdf
6. Jakobsen J.C., Nielsen E.E., Feinberg J., et al. Direct-acting antivirals for chronic hepatitis C (Review). Cochrane Database of Systematic Reviews. 2017, Jun 6; 6(6): CD012143. doi: 10.1002/ 14651858.CD012143.pub2.
7. Lacombe K., Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut. 2012; 61(Suppl 1):47—58. doi: 10.1136/gutjnl-2012-302062.
8. Qurishi N., Kreuzberg Ch., Luchters G., et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003; 22; 362(9397):1708—1713. doi: 10.1016/S0140-6736(03)14844-1.
9. Platt L., Easterbrook P., Gower E. et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infectious Diseases. 2016; 7: 797—808. doi: 10.1016/S1473-3099(15)00485-5.
10. [Balmasova I.P., Aristanbekova M.S., Malova E.S., Sepiashvili R.I. Mechanisms of interaction of viral pathogens in patients coinfected with human immunodeficiency viruses and hepatitis C. Zhurnal Мikrobiologii=Journal of Мicrobiology. 2016; 5:101-109. (In Russ.)]
11. Centers for Disease Control and Prevention. HIV Surveillance Report, 2016; V. 28. Available at: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published November 2017.
12. Kushner T., Prak C., Masand D. et al. Hepatitis C seroprevalence among consecutive labor and delivery admissions in two New York City hospitals. Open Forum Infectious Diseases. 2020 Oct 23; 7(11):ofaa514. doi: 10.1093/ofid/ofaa514.
13. Farsimadan M., Motamedifar M. The effects of human immunodeficiency virus, human papillomavirus, herpes simplex virus-1 and -2, human herpesvirus-6 and -8, cytomegalovirus, and hepatitis B and C virus on female fertility and pregnancy. British journal of biomedical science. 2021 Jan; 78(1):1—11. doi: 10.1080/ 09674845.2020.1803540.
14. Ray S.C., Bailey J.R., Thomas D.L. Hepatitis C virus. Chapter 27. // Fields virology. In: Knipe D.M., Howley P.M., Griffin D.E., et al. eds. Philadelphia: Lippincott Williams Wilkins, 2013; 1:795—824.
15. Freed E.O., Martin M.A. Human Immunodeficiency Viruses: Replication. Chapter 49. Fields virology. In: Knipe D.M., Howley P.M., Griffin D.E., et al. eds. Philadelphia: Lippincott Williams Wilkins, 2013; 2:1502—16560.
Review
For citations:
Khamatova A.A., Mazus A.I., Chebotareva T.A., Vlatskaya J.F., Tupoleva T.A., Tikhomirov D.S. Prevalence and features of the course of HIV/HCV co-infection in pregnant women. CHILDREN INFECTIONS. 2023;22(2):28-33. (In Russ.) https://doi.org/10.22627/2072-8107-2023-22-2-28-33
Views:
387
Email this article 